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Characterization of a novel myeloid antigen regulated 
during differentiation of monocytic cells*
The monoclonal antibody HC1/6 generated against phorbol 12-myristate 13-acetate- 
treated U-937 cells recognizes a new cell surface antigen with a broad relative molecu­
lar mass ranging from 100 to 150 kDa. This antigen is also present on monocytes, 
platelets and endothelial cells and is weakly expressed by granulocytes. In contrast, it 
is absent from T, B and erythroblastoid cells. The antigen HC1/6 is also expressed by 
normal tissue macrophages in tonsil, lung and kidney, as well as in skin biopsies from 
pathologies such as sarcoidosis and lepromatous leprosy. The expression of the HCl/6 
antigen is increased up to 5-fold when U-937 (promonocytic) and HL-60 
(myelomonocytic) cell lines are stimulated with phorbol 12-myristate 13-acetate. Con­
versely, the expression of the HCl/6 antigen is down-regulated in monocytes upon 
treatment with interferon-y. These findings are discussed in relation with other 
myeloid cell surface markers.
1 Introduction
The differentiation of monocytes is a multistep process charac­
terized by major changes in their morphological and functional 
properties [1, 2], These changes can correlate with the reg­
ulated expression of different cell surface antigens which are 
useful for the analysis of discrete stages of differentiation. A 
variety of agents including interferon (IFN)-y, retinoic acid 
(RA), phorbol 12-myristate 13-acetate (PMA) and 1,25-dihyd­
roxy vitamin D3 [l,25-(OH)2D3] are able to generate function­
ally different subpopulations and to regulate the expression of 
cell surface proteins of the monocytic lineage [3-7]. The exist­
ence of these subpopulations can be analyzed by using mono­
clonal antibodies (mAb) specific for surface antigens [8], 
Thus, CR3 (C D lib or Mol) is mainly present in circulating 
monocytes and granulocytes, whereas CDllc (pl50,95) is 
highly expressed in tissue macrophages (M<3>) [9-11]. Also, 
the expression of CR1 (CD35), CR3 (receptor for C3bi), 
C D llc and FcRI (CD16) is rapidly increased when cells are 
treated with certain stimuli such as IFN-y, PMA or the N- 
formyl-Met-Leu-Phe peptide [9-15].
The promonocytic cell line U-937 and the myelomonocytic cell 
line HL-60 have often been used to analyze the myeloid differ­
entiation process [16-18]. Here, we have used the M«J>-like 
U-937 cells after differentiation in the presence of PMA as a 
model system to generate mAb against novel cell surface anti­
gens of the myeloid family which are up-regulated after differ-
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entiation. Thus, we have obtained the mAb HCl/6 which rec­
ognizes a novel monocytic antigen of 100-150 kDa. The 
characterization of this antigen is described.
2 Materials and methods
2.1 Cell lines
U-937 (promonocytic), HL-60 (myelomonocytic), K-562 
(erythroblastoid), Jurkat (T lymphocytic), JM (T leukemic) 
and JY (B lymphoblastoid) cell lines were cultured in 
RPMI 1640 supplemented with 10% heat-inactivated fetal calf 
serum (FCS), 2 mM L -g lu tam in e ,  penicillin (100 U/ml) and 
streptomycin (100 ng/ml) (Flow Laboratories, Rockwell, 
MD), in a 5% CO2 atmosphere at 37 °C. When necessary, cells 
were treated with PMA (10 ng/ml), l,25-(OH)2D3 (10“s m), 
IFN-y (100 U/ml) or RA (100 ng/ml).
2.2 Preparation of leukocytes
Peripheral blood leukocytes were obtained from heparinized 
whole venous blood. After elimination of most erythrocytes by 
gravity sedimentation in the presence of 0.4% dextran, mono- 
, cytes (Mo) and lymphocytes were separated from granulocytes 
by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gra­
dient centrifugation. Granulocytes were obtained from the 
pellet and separated from contaminant erythrocytes by a 20-s 
hypotonic lysis in distilled water. Mo were isolated by incubat­
ing the mononuclear cell fraction in a slightly hypertonic 
medium followed by a second modified Ficoll-Hypaque 
density centrifugation [19], Alternatively, Mo were purified by 
centrifugal élutriation as described by Figdor et al. [20].
4
Mo (3 X 106/ml) were incubated at 37 °C, 5% CO2 and 100% 
humidity in Teflon bags (Jansen’s MNL, St. Niklaas, Belgium) 
in a modified Iscove’s medium containing human albumin and 
supplemented with 2% autologous heat-inactivated serum 
[21]. After 2 days in culture, Mo were collected from the Tef­
lon bags, washed, resuspended in phosphate-buffered saline 
(PBS) containing 0.5% bovine serum albumin, 0.02% sodium 
azide and kept on ice until the detection of surface membrane 
determinants. Platelets were obtained by density centrifuga­
tion [20].
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2.3 Reagents
Recombinant IFN-y (a gift from Dr. Adolf, Boehringer- 
Ingelheim, Vienna, Austria) was solubilized in RPMI 1640 
containing 10% FCS and stored at -20°C, l,25-(OH)2D3 
(a gift of Dr. Uskokovic, Hoffmann-La Roche, Nutley, NJ) 
and RA (Sigma, St. Louis, MO) were stored at -2 0 °C in 
ethanol, PMA (Sigma) was dissolved in dimethylsulfoxide to a 
concentration of 1 mg/ml.
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2.4 mAb
*
The mAb HC1/1 (anti-CDllc) [22], FG1/6 (specific for the 
transferrin receptor) [23], HP2/6 (anti-CD4) [24] and 8F3 
(anti-CD13) have been generated in our laboratory. The mAb 
Bear 1 (anti-CDllb) and Bear 2 (anti-CD14) [25, 26] were 
kindly provided by Dr. Jan De Vries (UNICET, Lyon, 
France). The mAb Q5/13, which detects a determinant com­
mon to HLA-DR, -DQ and -DP molecules [27], was a gift of 
Dr. S. Ferrone (New York Medical College, New York, NY).
2.5 Production of the hybridoma HCl/6
BALB/c mice were injected i.p . with 15 X 106 PMA-treated 
U-937 cells on days 48, 33 and i.v. on day 3 prior to fusion. 
Spleen cells were fused on day 0 with P3-X63Ag8.653 mouse 
myeloma cells at a 4:1  ratio according to standard techniques, 
distributed into 96-well plates (Costar, Cambridge, MA) and 
grown as described [22], After 2 weeks, hybridoma culture 
supernatants were harvested and screened for binding to 
PMA-differentiated U-937 cells using the 125I-labeled rat anti- 
mouse k chain mAb 187.1 as second antibody [28]. The mAb 
HCl/6 was selected due to its enhanced reactivity for PMA- 
treated over untreated U-937 cells. This antibody is of the 
IgGx subclass.
2.6 Radiolabeling, immunoprécipitation and electrophoresis
Cells were iodinated using chloroglycoluril (IODO-GEN, 
Sigma, [29]) and lysed in PBS, pH 7.4, containing 1% Triton 
X-100, 1% hemoglobin and 1 mM phenlymethylsulfonyl 
fluoride. Immunoprécipitation was carried out with protein A- 
Sepharose (Pharmacia; [22]) and samples were subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
[30] and autoradiography with enhancing screens [31].
2.7 Flow cytometry
Flow cytometry analysis was performed using either an 
EPICS-C (Coulter Cientificia, Mostoies, Spain) or a FACScan 
(Becton Dickinson, Mountain View, CA) flow cytometer 
using logarithmic amplifiers [22]. Specific fluorescence (SF) 
was obtained by subtracting the peak channel number of the 
negative control from the peak channel number of the corre­
sponding experimental sample.
2.8 Immunohistochemical staining of human tissue sections
Specimens of human tonsil, thymus, lymph node, brain, lung, 
skin and kidney were obtained by surgical procedures, Tissue
sections were stained by an indirect one-step immunoperoxi- 
dase method [22, 32]. For the double immunoperoxidase- 
alkaline phosphatase staining, we followed the sequential 
method reported by Masson et al. [33]. After the development 
of the peroxidase reaction, sections were incubated with the 
second mAb, then with a rabbit anti-mouse IgG, followed by a 
thhd incubation with the alkaline phosphatase-anti-alkaline 
phosphatase mAb complex (Dakopatts, Glostrup, Denmark). 
Each incubation was followed by three washes with Tris saline. 
Finally, the alkaline phosphatase reaction was developed, 
yielding a dark blue precipitate which contrasts with the brown 
colour of the peroxidase reaction. Sections were mounted in 
buffered gelatin for microscopic examination.
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3 Results
3.1 Effect of several differentiation agents on the expression of 
the antigen recognized by the mAb HCl/6
The mAb HCl/6 was obtained by immunization with PMA- 
treated U-937 cells. The antigen recognized by HCl/6 is mod* 
erately expressed on untreated U-937 cells, but its expression 
is strongly increased after PMA-induced differentiation 
(Fig. 1). IFN-y, l,25-(OH)2D3 and RA were also used to 
induce differentiation of U-937 cells and the expression of 
HCl/6 and several other cell surface markers was analyzed by 
flow cytometry (Fig. 1). The highest expression of the antigen 
recognized by the mAb HCl/6 was obtained in the presence of 
PMA. A certain augmentation of the HCl/6 antigen was also 
detected with IFN-y and l,25-(OH)2D3 in contrast to the 
decrease observed in the presence of RA. Concomitantly with 
the loss of proliferation (data not shown), the expression of 
the transferrin receptor was markedly diminished in every 
differentiation protocol. The regulation of the HCl/6 antigen 
expression is accompanied by different antigenic changes 
depending on the differentiation agent used. In addition to 
HCl/6, PMA enhances the expression of C D llc and CR3 
(CDllb) antigens and diminishes the expression of the CD4 
antigen. In the presence of l,25-(OH)2D3 and RA, CR3 
expression is also increased but the C D llc  antigen is almost 
unaffected. A feature common to RA and vitamin D3 but not 
to PMA is the marked decrease of the CD14 staining. On the 
other hand, CD4 expression was found to be affected only by 
RA and PMA. These results demonstrate that the expression 
of the antigen recognized by the mAb HCl/6 can be up-reg­
ulated by PMA, IFN-y and l,25-(OH)2D3. This regulation 
does not strictly follow any of the patterns shown by the anti­
genic markers used as controls. Kinetic studies in the presence 
of PMA demonstrated that the antigen HCl/6 shows the high­
est expression after 3 days in culture, similarly to the CDllc 
antigen (data not shown).
In vitro, IFN-y induces activation of human Mo, which is 
associated with an increased expression of the high-affinity 
FcR for IgG (FcyRI) and major histocompatibility complex 
(MHC) class II antigens [15, 34, 35], as well as a decreased 
expression of CD 14, CR3 and 63D3 antigens [36]. We then 
assayed the effect of IFN-y on the expression of the HCl/6 
antigen by human Mo (Table 1). Mo cultured in the presence 
of IFN-y showed a marked decrease in the expression of HCl/6 
as compared with the control culture. As expected, expression 
of MHC class II antigens increased during the culture of Mo 
but IFN-y and IFN-a up-regulated further their expression.
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Figure 1. Effect of different 
stimuli on the expression of the 
antigen recognized by the mAb 
H Cl/6. Unstimulated and PMA- 
(3 days), vitamin D3-(5 days), 
IFN-y-(5 days) or RA-(5 days) 
treated U-937 cells were incu­
bated with Bear 1 (anti-CDllb), 
HC1/1 (anti-CDllc), Bear 2 
(anti-CD 14), HCl/6 (anti-CD4), 
FG1/6 (anti-transferrin recep­
tor), 8F3 (anti-CD 13) or HCl/6 
mAb and assayed for indirect 
immunofluorescence in an 
EPICS-C flow cytometer as de­
scribed in Sect. 2.7. Arrows indi­
cate the increase or decrease in 
fluorescence after treatment of 
cells with the differentiation 
agents as compared to unstimu­
lated cells.
(A)
U-937
Untreated
PMA treated
HL-60 K-562 Jurkat JM JY
Fluorescence Intensity
(B)
Granulocytes Lymphocytes Monocytes Platelets
90
Fluorescence Intensity
Figure 2. Reactivity of the mAb HCl/6 with different cell types. Figures at the upper right corners represent the percentage of positive cells. (A) 
Untreated or PMA-treated U-937 (promonocytic), HL-60 (myelomonocytic), K-562 (erythroblastoid), Jurkat (T leukemic), JM (T leukemic) 
and JY (B lymphoblastoid) cell lines. (B) Peripheral blood granulocytes, lymphocytes, Mo and platelets. Cells were incubated with the HCl/6 
mAb and assayed for indirect immunofluorescence in an EPICS-C flow cytometer as described in Sect. 2,7*
Table 1. Effect of IFN-y and IFN-a on the expression of the antigen 
H C l/6 in Moa)
M r XlO
-3 1 2  3 4 5
a) Mo purified by the countercurrent élutriation method were incu­
bated in the absence or in the presence of IFN-y (100 U/ml) or 
IFN-a (100 U/ml) for 2 days at 37 °C in 5% C02. Cells were 
stained with either HCl/6 or the anti-HLA-DR mAb Q5/13 and 
their fluorescence was analyzed in a FACScan flow cytometer.
b) SF values were obtained as described in Sect. 2.7.
c) A control sample kept at 4°C was also included for comparison.
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Figure 3. Immunoprécipi­
tation analysis of the anti­
gen recognized by the mAb 
H C l/6. PMA-treated U-937 
cells were 125I-labeled, 
lysed and immunoprecipi- 
tated with HCl/6 (lanes 2 
and 4), anti-CDllc (lane 3) 
or a negative control 
(lanes 1 and 5) mAb. Sam­
ples were electrophoresed 
under either reducing 
(lanes 1-3) or nonreducing 
(lanes 4 and 5) conditions.
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Figure 4. Immunoperoxidase staining of tonsil (A), kidney (B) and lung (C) sections with the mAb HC1/6. (D) shows a double staining of a lung 
section with the mAb HC1/1 (peroxidase) followed by the mAb HC1/6 (alkaline phosphatase). The mAb HC1/6 recognizes the M<E> present in all 
these tissues as well as the high endothelial venules (A). Staining of the renal glomerulus (B) shows an intense labeling of mesangial cells together 
with a diffuse reactivity of capillaries. Samples (A), (B) and (C) were hematoxylin counterstained. Magnification: (A, B; x 250); (C, D; X 400).
I
No changes in the level of expression of the antigen HC1/6 
were obtained in the presence of IFN-a.
Other cell types were also assayed for reactivity with the mAb 
HC1/6 (Fig. 2), No staining was found with the erythroblastoid 
cell line K-562 nor with the lymphoblastoid B cell line JY and 
the T cell line JM. Similarly, a very weak reactivity was found 
with the T cell leukemic line Jurkat. In addition, granulocytes 
were weakly labeled by the mAb HC1/6, whereas peripheral 
blood Mo and platelets were clearly positive as opposed to the 
negative staining of lymphocytes. The relatively restricted 
expression of this antigen to cells of the myeloid lineage (U- 
937, HL-60, Mo and platelets) becomes also apparent after 
study of different cell types treated with PMA (Fig. 2). Only 
the promonocytic cell line U-937 and the myelomonocytic cell 
line HL-60 showed an increased expression of the antigen in 
response to PMA. This contrasts with the negative response of 
T, B and erythroblastoid cell lines.
As determined by immunoprécipitation analysis under reduc­
ing conditions, a broad band of 100-150 kDa was recognized 
by the mAb HC1/6 from cell surface radioiodinated U-937 cells 
after differentiation in the presence of PMA (Fig. 3, lane 2). 
The same relative molecular mass (Mr) was obtained under 
nonreducing conditions (lane 4) demonstrating the absence of 
interchain disulfide bonds. The CDllc/CD18 antigen complex
was also immunoprecipitated for comparative purposes 
(lane 3).
3.2 Detection of the antigen recognized by the mAb HC1/6 in 
tissue MO
The antigen recognized by the mAb HC1/6 was visualized by 
immunoperoxidase staining of frozen tissue sections. Thus, 
MO from tonsil, lung and kidney were labeled by the mAb 
HC1/6 (Fig. 4). Scattered macrophages in the paracortical area 
(T cell zone) from tonsil (A), alveolar MO from lung (C) and 
mesangial MO from kidney glomeruli (B) were positively 
stained with mAb HC1/6. In addition, Kupffer cells from liver 
as well as MO from lymph node and thymus were labeled by 
mAb HC1/6, whereas microglial cells and dendritic epidermal 
cells were negative (data not shown). In most of these tissues, 
the presence of the HC1/6 antigen was evident in endothelial 
cells. Since the CDllc antigen is an excellent marker for tissue 
MO, we carried out a double staining with HC1/6 and anti- 
CD 11c mAb (D). As shown by immunoperoxidase/alkaline 
phosphatase staining, the C D llc (brown) and HC1/6 (dark 
blue) antigens are co-expressed by the majority of MO. How­
ever, the HC1/6 antigen was expressed on vascular structures 
whereas the C D llc antigen was not.
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Different pathologies characterized by the presence of an 
increased number of activated MO were also analyzed by 
staining of skin sections with the mAb HC1/6. In lepromatous 
leprosy and sarcoidosis, most of the infiltrating MO, as well 
as the epithelioid and giant cells present in the granulomas ex­
pressed the HC1/6 antigen (data not shown).
4 Discussion
The mAb HC1/6 described here recognizes a protein with 
a broad Mr ranging from 100 to 150 kDa and which seems to 
be specific for the myeloid lineage. This antigen is highly ex­
pressed on peripheral blood Mo, tissue MO, platelets, 
endothelial cells and, upon differentiation, on the MO-like U- 
937 and HL-60 cells.
The expression of the antigen HC1/6 on Mo is not due to 
activation during the isolation protocol [37], since the same 
results were obtained when Mo were purified by the counter- 
current elutriation method [20]. In this sense, activation of Mo 
in the presence of IFN-y down-regulates the expression of the 
antigen HC1/6 in contrast with an increased expression of 
MHC class II antigens. Although IFN-y promotes differentia­
tion of Mo into activated MO with cytotoxic activity and 
increased expression of MHC class II and FcR, certain 
myeloid differentiation antigens such as CD14 (Mo2) and 
63D3 are down-regulated [36], This is in agreement with the 
behavior of the antigen HC1/6 in the presence of IFN-y but not 
observed in the presence of IFN-a.
Other myeloid antigens with a similar Mr as HC1/6 but differ­
ent characteristics have been described [8,9,38,39]. Thus, the 
antigens CDllb and C D llc  are associated with a second |3 
subunit (CD18) and are not present on peripheral platelets, as 
opposed to HC1/6. On the other hand, mAb of the CD13 
cluster which are specific for a 150-kDa protein, differ from 
the antigen HC1/6 in their strong reactivity for bile canaliculi 
and granulocytes, the lack of staining of platelets and the dis­
tinct behavior upon stimulation with different agents (Fig. 1), 
Moreover, the CD31 antigen (sharp band at 130 kDa), 
although present on platelets,is highly expressed by peripheral 
granulocytes as well as by the T cell lines Jurkat and CEM as 
opposed to the antigen HC1/6 (broad band at 100-150 kDa).
A  review of other unclustered antigens reveals that none is 
identical to the HC1/6 antigen. The |3 subunit of the VLA 
complex (110 kDa unreduced, 130 kDa reduced) which is 
identical to the gplla [30], is also present in platelets. How­
ever, this antigen is different from HC1/6 since: (a) the Mr of 
gplla changes between reducing or nonreducing conditions 
and (b) mAb directed against this antigen strongly react with 
the erythroblastoid cell line K-562 [41, 42]. Moreover, mAb 
MoU26, which recognizes a 130-140-kDa antigen [38] is dis­
tinct from the mAb HC1/6 due to the differential cellular reac­
tivity since MoU26 strongly labels K-562 and does not react 
with Mo. Finally, the mAb CLB-HEC-75, which recognizes a 
150-kDa antigen present on platelets and endothelial cells, 
is absent from Mo [43] and does not compete with the mAb 
HC1/6 for binding to PMA-treated U-937 cells (data not 
shown).
The mAb HC1/6 reacts with most of the vessels (venules, 
veins, small arteries and capillaries) and specially with high 
endothelial venules. Similarly, the ICAM-1 antigen and other
members of the integrin superfamily are also expressed by 
endothelial cells [44]. Interestingly, the ICAM-1 antigen 
(ligand for LFA-1 antigen) is also up-regulated by PMA in 
U-937 and HL-60 ceils [45 , 46]. Since the antigens of the inte­
grin family are involved in cell-matrix and cell-cell interac­
tions, a similar function could be suggested for the antigen 
HC1/6, However, we have been unable to assign any func­
tional role to the antigen HC1/6. In our hands, adhesion, mig­
ration antigen presentation and antibody-dependent cell- 
mediated cytotoxicity of Mo are unaffected by the presence of 
the mAb HC1/6. The fact that this antigen is not only present 
on Mo/MO but also in platelets, suggests that the function of 
the antigen HC1/6 is shared by both lineages.
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Note added in proof: While this manuscript was in press we found out 
that the mAb HC1/6 is reactive with transfectants of COS-7 cells ex­
pressing the CD31 antigen.
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